1. Home
  2. NLOP vs DBVT Comparison

NLOP vs DBVT Comparison

Compare NLOP & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NLOP
  • DBVT
  • Stock Information
  • Founded
  • NLOP N/A
  • DBVT 2002
  • Country
  • NLOP United States
  • DBVT France
  • Employees
  • NLOP N/A
  • DBVT N/A
  • Industry
  • NLOP
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NLOP
  • DBVT Health Care
  • Exchange
  • NLOP Nasdaq
  • DBVT Nasdaq
  • Market Cap
  • NLOP 435.5M
  • DBVT 464.0M
  • IPO Year
  • NLOP N/A
  • DBVT N/A
  • Fundamental
  • Price
  • NLOP $29.20
  • DBVT $14.36
  • Analyst Decision
  • NLOP Strong Buy
  • DBVT Buy
  • Analyst Count
  • NLOP 1
  • DBVT 5
  • Target Price
  • NLOP $46.00
  • DBVT $15.85
  • AVG Volume (30 Days)
  • NLOP 59.6K
  • DBVT 172.8K
  • Earning Date
  • NLOP 11-19-2025
  • DBVT 10-28-2025
  • Dividend Yield
  • NLOP 10.61%
  • DBVT N/A
  • EPS Growth
  • NLOP N/A
  • DBVT N/A
  • EPS
  • NLOP N/A
  • DBVT N/A
  • Revenue
  • NLOP $117,598,000.00
  • DBVT $5,502,000.00
  • Revenue This Year
  • NLOP N/A
  • DBVT $1,743.46
  • Revenue Next Year
  • NLOP N/A
  • DBVT $1,044.34
  • P/E Ratio
  • NLOP N/A
  • DBVT N/A
  • Revenue Growth
  • NLOP N/A
  • DBVT N/A
  • 52 Week Low
  • NLOP $26.10
  • DBVT $2.21
  • 52 Week High
  • NLOP $34.53
  • DBVT $18.00
  • Technical
  • Relative Strength Index (RSI)
  • NLOP 48.48
  • DBVT 51.23
  • Support Level
  • NLOP $28.93
  • DBVT $13.70
  • Resistance Level
  • NLOP $29.55
  • DBVT $15.97
  • Average True Range (ATR)
  • NLOP 0.45
  • DBVT 1.06
  • MACD
  • NLOP 0.03
  • DBVT -0.40
  • Stochastic Oscillator
  • NLOP 54.21
  • DBVT 15.71

About NLOP Net Lease Office Properties of Beneficial Interest

Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns a diversified portfolio of office properties that are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its net leases generally specify a base rent with rent increases and require the tenant to pay substantially all costs associated with operating and maintaining the property. Its portfolio includes approximately 1.2 million square feet of Green-Certified Buildings, 2 LEED-certified buildings, and 1 BREEAM-certified building.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: